Vertex forges ahead with one hep C prospect, nixes another

A little more than a year after Vertex licensed in a pair of "nucs" from Alios BioPharma in a high-stakes bid to develop an oral, interferon-free approach to hepatitis C, Vertex ($VRTX) is jettisoning one as a dud while racing ahead with the second into a mid-stage study slated to begin in a matter of weeks. Report